DAR-100A

Phase 1Small molecule

NNew York State Psychiatric Institute

DAR-100A is one of 25 small molecule programs targeting Psychiatric Disorder. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psychiatric DisorderActive, not recruiting

Psychiatric DisorderPhase 1

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Psychiatric Disorder

#DrugCompanyPhaseTrials

Wellbutrin

GSK

Approved

2 2

Chantix

Pfizer

Approved

2 3

Lexapro

AbbVie

Approved

1 4

Nicorette

Pfizer

Approved

1 5

Chantix

PPrism Pharmaceuticals

Approved

1 6

Nicotine Free Cigarettes

Pfizer

Approved

2 7

Suboxone

Pitocin

Brintellix

1 10

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psychiatric Disorder1 trial

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

Completed·NNew York State Psychiatric Institute·Phase 1·NCT01519557·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DAR-100A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DAR-100A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DAR-100A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York State Psychiatric Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNew York State Psychiatric Institute

DAR-100A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Psychiatric Disorder1 trial

References

Drug Info

Quick Facts

Related News